CN100409880C - Mongolian medicine Baolier for treating hyperlipemia and method for preparing same - Google Patents
Mongolian medicine Baolier for treating hyperlipemia and method for preparing same Download PDFInfo
- Publication number
- CN100409880C CN100409880C CNB2006100804253A CN200610080425A CN100409880C CN 100409880 C CN100409880 C CN 100409880C CN B2006100804253 A CNB2006100804253 A CN B2006100804253A CN 200610080425 A CN200610080425 A CN 200610080425A CN 100409880 C CN100409880 C CN 100409880C
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- fructus
- medicine
- hyperlipemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 201000005577 familial hyperlipidemia Diseases 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title description 13
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 241000628997 Flos Species 0.000 claims description 12
- 241000180649 Panax notoginseng Species 0.000 claims description 12
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 11
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 241000132446 Inula Species 0.000 claims description 3
- 241000498779 Myristica Species 0.000 claims description 3
- 241000545442 Radix Species 0.000 claims description 3
- 241000001522 Terminalia chebula Species 0.000 claims description 3
- 240000001972 Gardenia jasminoides Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 10
- 108010023302 HDL Cholesterol Proteins 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 5
- 235000012000 cholesterol Nutrition 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 244000111489 Gardenia augusta Species 0.000 abstract description 3
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 2
- 208000018152 Cerebral disease Diseases 0.000 abstract description 2
- 208000007536 Thrombosis Diseases 0.000 abstract description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 2
- 230000000977 initiatory effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000871539 Choerospondias Species 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 244000116484 Inula helenium Species 0.000 abstract 1
- 235000002598 Inula helenium Nutrition 0.000 abstract 1
- 244000270834 Myristica fragrans Species 0.000 abstract 1
- 235000009421 Myristica fragrans Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000000513 Santalum album Species 0.000 abstract 1
- 235000008632 Santalum album Nutrition 0.000 abstract 1
- 230000001174 ascending effect Effects 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000001702 nutmeg Substances 0.000 abstract 1
- 244000138993 panchioli Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 17
- 241000700159 Rattus Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JSNRRGGBADWTMC-UHFFFAOYSA-N (6E)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene Chemical compound CC(C)=CCCC(C)=CCCC(=C)C=C JSNRRGGBADWTMC-UHFFFAOYSA-N 0.000 description 2
- 239000001306 (7E,9E,11E,13E)-pentadeca-7,9,11,13-tetraen-1-ol Substances 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- PXOYOCNNSUAQNS-AGNJHWRGSA-N alantolactone Chemical compound C1[C@H]2OC(=O)C(=C)[C@H]2C=C2[C@@H](C)CCC[C@@]21C PXOYOCNNSUAQNS-AGNJHWRGSA-N 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BNWJOHGLIBDBOB-UHFFFAOYSA-N myristicin Chemical compound COC1=CC(CC=C)=CC2=C1OCO2 BNWJOHGLIBDBOB-UHFFFAOYSA-N 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- KWFJIXPIFLVMPM-KHMAMNHCSA-N (+)-alpha-santalene Chemical compound CC(C)=CCC[C@]1(C)[C@@H]2C[C@H]3[C@@H](C2)[C@@]13C KWFJIXPIFLVMPM-KHMAMNHCSA-N 0.000 description 1
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- PGBNIHXXFQBCPU-ILXRZTDVSA-N (-)-beta-santalene Chemical compound C1C[C@H]2C(=C)[C@@](CCC=C(C)C)(C)[C@@H]1C2 PGBNIHXXFQBCPU-ILXRZTDVSA-N 0.000 description 1
- SNKFFCBZYFGCQN-PDVBOLEISA-N (2r)-2-[(e)-3-[(2r,3r)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-PDVBOLEISA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- JSNRRGGBADWTMC-QINSGFPZSA-N (E)-beta-Farnesene Natural products CC(C)=CCC\C(C)=C/CCC(=C)C=C JSNRRGGBADWTMC-QINSGFPZSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- PDEQKAVEYSOLJX-UHFFFAOYSA-N Hexahydronerolidol Natural products C1C2C3(C)C2CC1C3(C)CCC=C(CO)C PDEQKAVEYSOLJX-UHFFFAOYSA-N 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical group C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- XWQLUVQFUZQPDY-UHFFFAOYSA-N Sesquifenchene Natural products CC(=CCCC1(C)C2CCC1C(=C)C2)C XWQLUVQFUZQPDY-UHFFFAOYSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- PXOYOCNNSUAQNS-UHFFFAOYSA-N alantolactone Natural products C1C2OC(=O)C(=C)C2C=C2C(C)CCCC21C PXOYOCNNSUAQNS-UHFFFAOYSA-N 0.000 description 1
- PDEQKAVEYSOLJX-AIEDFZFUSA-N alpha-Santalol Natural products CC(=CCC[C@@]1(C)[C@H]2C[C@@H]3[C@H](C2)[C@]13C)CO PDEQKAVEYSOLJX-AIEDFZFUSA-N 0.000 description 1
- KWFJIXPIFLVMPM-BSMMKNRVSA-N alpha-santalene Natural products C(=C\CC[C@]1(C)C2(C)[C@H]3[C@@H]2CC1C3)(\C)/C KWFJIXPIFLVMPM-BSMMKNRVSA-N 0.000 description 1
- PDEQKAVEYSOLJX-BKKZDLJQSA-N alpha-santalol Chemical group C1C2[C@]3(C)C2C[C@H]1[C@@]3(C)CC/C=C(CO)/C PDEQKAVEYSOLJX-BKKZDLJQSA-N 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- OJYKYCDSGQGTRJ-INLOORNJSA-N beta-Santalol Natural products C1C[C@H]2C(=C)[C@](CC\C=C(CO)/C)(C)[C@@H]1C2 OJYKYCDSGQGTRJ-INLOORNJSA-N 0.000 description 1
- YSNRTFFURISHOU-UHFFFAOYSA-N beta-farnesene Natural products C=CC(C)CCC=C(C)CCC=C(C)C YSNRTFFURISHOU-UHFFFAOYSA-N 0.000 description 1
- OJYKYCDSGQGTRJ-GQYWAMEOSA-N beta-santalol Chemical compound C1C[C@H]2C(=C)[C@@](CC/C=C(CO)/C)(C)[C@@H]1C2 OJYKYCDSGQGTRJ-GQYWAMEOSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- -1 lauro lene Chemical compound 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
The present invention relates to a medicine and a preparation method thereof, namely a Mongolian medicine Baolier which has obvious therapeutic effect on hyperlipemia and a preparation process thereof. The hyperlipemia is an important factor which is the initiation of cardio-cerebral diseases, such as the thrombosis, the arteriosclerosis, the coronary disease, etc. Oral administration medicines which has the advantages of convenient administration, small toxicity and side effects and obvious curative effect are deficient at present. On the basis of Mongolian medicine prescriptions, the present invention adopts a modern technology, axillary choerospondias fruit, red sage roots, elecampane, nutmeg, gardenia, sandalwood, milkvetch roots, dalbergia wood, safflower, radices pseudoginseng, bezoar, musk, etc. are used as main raw materials for preparing the Mongolian medicine Baolier. A great number of experiments and clinical applications show that the Baolie has the efficacy on promoting flow of qi and blood circulation, absorbing clots and relieving stagnancy, and ascending the clear and descending the turbid; the Baolie can reduce blood fat, total cholesterol and triglyceride, has relatively obvious function of enhancing the contents of high density lipoprotein cholesterol, and has exact therapeutic effect on hyperlipemia.
Description
Technical field
The present invention is a kind of medicine and method for making thereof, promptly a kind of mongolian medicine Poly you and manufacturing process thereof that hyperlipemia is had significant curative effect.
Background technology
Hyperlipidemia is a lipid metabolic disorder, a class disease that causes blood low density cholesterol, content of triglyceride to exceed standard.Reduction along with growth in the living standard and physical labor intensity, it has been established that, hyperlipemia is to cause the key factor of cardio-cerebral diseases such as thrombosis, arteriosclerosis, coronary heart disease, that the patient gently then shows as is uncomfortable in chest, breathe hard, ambition twinge, dizzy, headache, heavy then cause cordis and cerebral accident, disability rate and mortality rate are high.Along with the reduction of growth in the living standard and physical labor intensity, the cardiovascular and cerebrovascular disease of hyperlipidemia and initiation thereof has become frequently-occurring disease, and commonly encountered diseases is to the people's health formation threat greatly.Be the minority area of main diet with meat, milk and drinks particularly, the sickness rate of cardiovascular and cerebrovascular disease is high especially, is badly in need of taking measures necessary.At present, the medicine for the treatment of this type of disease is a lot, and, taking convenience, toxic side effect oral medicine little, evident in efficacy also relatively lack.Mongolian medicine is with a long history, and is abundant in content, is the important component part of motherland's medical treasure-house, wherein is no lack of the definite curative effect of medicine and prescription have to(for) cardiovascular and cerebrovascular disease., for a long time, under the tide that western medicine develops rapidly impacted, the valuable intension of mongolian medicine did not obtain due attention and raising, and many classical theories and prescription are scattered among the people.In recent years, along with back to nature, advocate the formation of modish theories such as green, always with the medicated diet homology, natural pure be the favor that the mongolian medicine of characteristics has been subjected to people again, people more wish to seek to solve the approach of cardiovascular and cerebrovascular disease in the treasure-house of Mongolian medicine's mongolian medicine.
Summary of the invention
The purpose of this invention is to provide a kind of mongolian medicine that hyperlipemia is had significant curative effect.
To achieve these goals, we are according to five yuan of theories of Mongolian medicine's negative and positive and three seven plain six disease disease theories, and five yuan of mongolian medicine, Six-element, eight property, 17 are imitated theoretical, adopt advanced modern technologies and experimental technique, by collecting widely and repeated screening, determined your following component (consumption is a weight portion) of mongolian medicine Poly:
Fructus Choerospondiatis 110-120 part, Radix Salviae Miltiorrhizae 110-120 part, Radix Inulae 110-120 part; Semen Myristicae 18-30 part, Fructus Gardeniae 35-45 part, Lignum Santali Albi 18-30 part; Radix Astragali 52-65 part, Lignum Dalbergiae Odoriferae 35-45 part, Flos Carthami 35-45 part; Radix Notoginseng 35-45 part, Fructus Toosendan 35-45 part, Radix Rubiae 52-65 part; Radix Ophiopogonis 35-45 part, Radix Aucklandiae 8-15 part, Radix Et Rhizoma Rhei 8-15 part; Fructus Chebulae 35-45 part, Calculus Bovis 5-12 part, Moschus 0.5-1.8 part.
The optimization parts by weight of component of said medicine is: Fructus Choerospondiatis 114-118 part, Radix Salviae Miltiorrhizae 114-118 part, Radix Inulae 114-118 part; Semen Myristicae 20-25 part, Fructus Gardeniae 38-42 part, Lignum Santali Albi 20-25 part; Radix Astragali 56-60 part, Lignum Dalbergiae Odoriferae 38-42 part, Flos Carthami 38-42 part; Radix Notoginseng 38-42 part, Fructus Toosendan 38-42 part, Radix Rubiae 56-60 part; Radix Ophiopogonis 38-42 part, Radix Aucklandiae 10-12 part, Radix Et Rhizoma Rhei 10-12 part; Fructus Chebulae 38-42 part, Calculus Bovis 7-10 part, Moschus 0.8-1.3 part.
Optimum weight part component of said medicine is: 116 parts of Fructus Choerospondiatis, 116 parts of Radix Salviae Miltiorrhizaes, 116 parts of Radix Inulaes; 23 parts of Semen Myristicaes, 40.4 parts of Fructus Gardeniaes, 23 parts in Lignum Santali Albi; 58 parts of the Radixs Astragali, 40.4 parts of Lignum Dalbergiae Odoriferaes, 40.4 parts on Flos Carthami; 40.4 parts of Radix Notoginseng, 40.4 parts of Fructus Toosendans, 58 parts in Radix Rubiae; 40.4 parts of Radix Ophiopogonis, 11.5 parts of the Radix Aucklandiae, 11.5 parts of Radix Et Rhizoma Rhei; 40.4 parts of Fructus Chebulaes, 8.6 parts of artificial Calculus Boviss, 1.15 parts of artificial Moschuss.
Manufacturing method for above mentioned medicine is: Radix Salviae Miltiorrhizae, Radix Inulae are added alcohol reflux filter to such an extent that extracting solution and medicinal residues are standby; Fructus Choerospondiatis, the Radix Astragali, Fructus Gardeniae, Flos Carthami, Fructus Toosendan, Radix Rubiae, Radix Ophiopogonis, Radix Et Rhizoma Rhei, Fructus Chebulae's 9 flavors are merged with above-mentioned medicinal residues, and decocting boils gets filtrate, adds Radix Salviae Miltiorrhizae, Radix Inulae extracting solution, is condensed into thick paste, standby; Lignum Dalbergiae Odoriferae, Radix Notoginseng, Semen Myristicae, Lignum Santali Albi, Radix Et Rhizoma Rhei 5 flavor medicine mixed powders are broken into powder, mix thoroughly with above-mentioned thick paste, with Moschus, Calculus Bovis convert be mixed even.
The concrete preparation method of this medicine is: after choosing crude drug by standard, with Radix Salviae Miltiorrhizae, Radix Inulae decoction pieces, add 2.5-3.2 and doubly measured alcohol reflux 1.3-1.8 hour, filter, medicinal residues are standby, and are behind the decompression filtrate recycling ethanol, standby; Fructus Choerospondiatis, the Radix Astragali, Fructus Gardeniae, Flos Carthami, Fructus Toosendan, Radix Rubiae, Radix Ophiopogonis, Radix Et Rhizoma Rhei, Fructus Chebulae's 9 flavors are merged with above-mentioned medicinal residues, and decocting boils, and gradation filters, merging filtrate, add Radix Salviae Miltiorrhizae, Radix Inulae extracting solution, be condensed into relative density and be the thick paste of 1-1.5 (75-85 ℃), standby; Lignum Dalbergiae Odoriferae, Radix Notoginseng, Semen Myristicae, Lignum Santali Albi, Radix Et Rhizoma Rhei 5 flavor medicine mixed powders are broken into powder, mix thoroughly with above-mentioned thick paste, dry below 60 ℃, be ground into fine powder, convert with Moschus, Calculus Bovis fine powder and be mixed evenly, to granulate, drying incapsulates.
The mongolian medicine that adopts technique scheme to make, have promoting flow of QI and blood, blood stasis dispelling disappear stagnant, give birth to clear the turbid descending, in a large amount of experiments and clinical practice, show significant blood fat reducing, hypercholesterolemia reducing, triglyceride, promote the effect of HDL-C content, hyperlipemia is had definite curative effect.
In order to verify your curative effect of Poly, Inner Mongolia Mongolian Medicine Co., Ltd. has carried out strict zoopery and clinical trial, and its concise and to the point process and result are as follows:
One, zoopery: 1, experiment material
Laboratory animal, Kunming mouse, body weight 18-22g, ♂ or ♀ ♂ dual-purpose, Wistar kind rat, property, body weight 180-250g.
Experimental drug: 0.39/ of Poly that capsule, content is 2.9g crude drug/g powder, does not contain auxiliary element, factory provides by Inner Mongol mongolian medicine.
Experimental apparatus: 752 type ultraviolet grating spectrophotometers (Shanghai the 3rd analytical tool factory) the multi-functional platelet aggregation instruments of SPA-4 (Shanghai Kodak test instrunment factory), LIANG100 microcomputer show record blood plasma viscometer (produce Shanghai Medical Univ Medical Instruments development center) automatically.
2, experimental technique and result
2.1 Poly that capsule is to the influence of normal mice serum TC content
Get 40 of male mices, be divided into 4 groups at random, press the gastric infusion of dosage shown in the table 1, every day 1 time, continuous 10 days, matched group is irritated stomach consubstantiality hydrops 100ml/kg, fasting 16h after the last administration, the blood sampling of mouse orbit venous plexus, separation of serum, adopt the direct development process of o-phthalaldehyde(OPA) (1) to measure serum total cholesterol (TC) content, it the results are shown in Table 1.
Table 1 Poly that capsule is to the influence of normal mice serum TC content
| Group and dosage (g/kg) | Number of animals (n) | TC content (mmcl/L in the serum; ± SD) |
| Normal control group Poly that 4.50 2.25 1.13 | 10 10 10 10 | 3.77±0.92 3.62±0.54 3.62±0.60 3.76±0.84 |
The result shows: though Poly that capsule has reduction trend to TC content in the normal mice serum, no statistical significance illustrates that your capsule of Poly does not have obvious influence to normal mice serum TC content in this dosage range.
2.2 the influence of the hyperlipemia in mice serum TC content that your capsule of Poly causes egg yolk
Get 50 of male mices, be divided into 5 groups at random, dosage and method are with experiment 2.1, fasting 16h after the last administration, except that the normal control group, all the other 4 groups equal ip75% egg yolk Emulsion 0.5ml/, mouse orbit venous plexus blood sampling in 20h, separation of serum is surveyed its TC content, the results are shown in Table 2.
Your capsule of table 2 Poly to egg yolk cause the influence of blood fat mass formed by blood stasis mice serum TC content
| Group and dosage (g/kg) | Number of animals (n) | TC content (mmcl/L in the serum; ± SD) |
| Normal control group hyperlipidemia model group Poly that 4.50 2.25 1.13 | 10 10 10 10 10 | 3.77±0.92 △△△ 7.92±0.98 6.79±0.83 ** 5.96±1.02 *** 6.26±0.92 *** |
Table 2 is the result show, you all have remarkable reduction effect to hyperlipemia in mice serum TC content by capsule Poly.
2.3 Poly that capsule is to the influence of hyperlipidemia rats serum lipids and HDL-C content
Get 40 of male rats, be divided into 5 groups at random, press the gastric infusion of dosage shown in the table 3, every day 1 time, continuous 20 days, administration except that the normal control group, was all fed high cholesterol diet for all the other 4 groups simultaneously.(prescription: yolk powder 10%, Adeps Sus domestica 5%, cholate 0.5%, normal diet 85%), fasting 16h behind the last medicine, the blood sampling separation of serum is surveyed its TC content, adopts acetylacetone method to measure serum triglycerides (TC) content, surveys its HDL-C (HL-C) content.The results are shown in Table 3.
Table 3 Poly that capsule is to the influence of hyperlipidemia rats serum lipids and HDL-C content
Obviously reduce the content of TC and TC in the serum by your capsule of the visible Poly of table 3, improve HDL-C content.
2.4 your capsule of Poly refers to the influence of mass formed by blood stasis hemorheology of rat to height
Get 40 of male rats, be divided into 5 groups at random, press gastric infusion of dosage shown in the table 4 and moulding, its method is with experiment 2.3, fasting 1h behind the last medicine with 3% pentobarbital sodium anesthetized rat (30g/kg), takes a blood sample through ventral aorta, anticoagulant heparin writes down blood plasma viscometer determining hemorheological indexes automatically with the LLANG-100 microcomputer.See Table 4
Table 4 Poly that capsule is to the hemorheological influence of hyperlipidemia rats
The result shows that you significantly reduce the hyperlipidemia rats blood viscosity by capsule Poly.
2.5 Poly that capsule is to the influence of rat platelet aggregation function
Get 40 of male rats, be divided into 4 groups at random, press the gastric infusion of dosage shown in the table 5, every day 1 time, continuous 20 days, fasting 1h behind the last medicine, with 3% pentobarbital sodium anesthetized rat (30g/kg), through the ventral aorta blood sampling, put the multi-functional platelet aggregation instrument of SPA-4 after preparation PRP and the PPP, be that derivant is measured platelet aggregation rate (5min) with ADP.
Table 5 Poly that capsule is to the influence of rat platelet aggregation function
| Group and dosage (g/kg) | Number of animals (n) | 5min platelet aggregation rate (ADP) (%, ± SD) |
| Normal control group Poly that 4.50 2.25 1.13 | 10 10 10 10 | 53.40±9.31 28.39±12.59 *** 27.69±13.35 *** 34.53±9.88 *** |
Table 5 shows that you significantly suppress the inductive platelet aggregation of ADP by capsule Poly.
2.6 Poly that capsule is to the influence of clotting time of mice
Get 40 of mices, be divided into 4 groups at random, dosage sees Table 6,, every day 1 time, continuous irrigation stomach 15 days, fasting 1h after the last administration surveys its clotting time by slide method, the results are shown in Table 6.
Table 6 Poly that capsule is to the influence of mouse platelets aggregation capability
| Group and dosage (g/kg) | Number of animals (n) | Clotting time (min, ± SD) |
| Normal control group Poly that 4.50 2.25 1.13 | 10 10 10 10 | 0.75±0.35 1.20±0.43 * 1.33±0.52 ** 1.17±0.53 * |
The result shows, Poly that capsule significant prolongation clotting time of mice.
Illustrate: among the table 2-4, △ normal control group and hyperlipidemia model group are relatively; * administration group and hyperlipidemia model group are relatively.△ or * P＜0.05, △ △ or * * P＜0.01, △ △ △ or * * * P＜0.001.
Two, clinical trial: " clinical drug trial management regulation " according to State Food and Drug Administration's promulgation carried out II phase and III clinical trial phase.Wherein, clinical trial phase is observed 200 examples altogether, adopts the randomized controlled test method.Wherein, Poly that test group 100 examples, JIANGZHILING matched group 100 examples.The result shows: Poly you for hyperlipemia clinic control 24 examples, produce effects 28 examples, effective 31 examples, cure-remarkable-effectiveness rate 52%, effective percentage 83%, with matched group relatively, P＜0.01.Traditional Chinese medical science disease clinic control 4 examples, produce effects 50 examples, effective 40 examples, cure-remarkable-effectiveness rate 54%, total effective rate 94% compares P＜0.01 with matched group.
You observe 400 examples by the III clinical trial phase altogether Poly, adopt single at random blind controlled trial method.Wherein, Poly that test group 300 examples, JIANGZHILING matched group 100 examples.The result shows: Poly you for hyperlipemia clinic control 77 examples, produce effects 78 examples, effective 77 examples, cure-remarkable-effectiveness rate 51.7%, total effective rate 77.3%, with matched group relatively, P＞0.05.Traditional Chinese medical science disease clinic control 63 examples, produce effects 136 examples, effective 73 examples, cure-remarkable-effectiveness rate 66.3%, total effective rate 90.7% compares P＞0.05 with matched group.
In II clinical trial phase and III clinical trial phase, medicine hypercholesterolemia reducing, triglyceride have been analyzed, the pure curative effect that the high density lipoprotein increasing gallbladder is solid.Through check, there was no significant difference between test group and matched group group, but self relatively learns by statistics and handles before and after the test group treatment, and there is significant differences P＜0.01.Illustrate that investigational agent has hypercholesterolemia reducing, triglyceride preferably, the effect of high density lipoprotein increasing cholesterol.
In II clinical trial phase and III clinical trial phase, safety index is observed, all do not find untoward reaction.By to patient blood before and after the test, urine, just, the analysis of the inspection data of routine, liver function (GPT, BUN, CR), electrocardiogram, blood pressure, heart rate, all do not find toxic and side effects, show that this medicine is safe.
The specific embodiment
Introduce a kind of capsular embodiment of Poly that produces below.
Prescription: 116 parts of Fructus Choerospondiatis, 116 parts of Radix Salviae Miltiorrhizaes, 116 parts of Radix Inulaes; 23 parts of Semen Myristicaes, 40.4 parts of Fructus Gardeniaes, 23 parts in Lignum Santali Albi; 58 parts of the Radixs Astragali, 40.4 parts of Lignum Dalbergiae Odoriferaes, 40.4 parts on Flos Carthami; 40.4 parts of Radix Notoginseng, 40.4 parts of Fructus Toosendans, 58 parts in Radix Rubiae; 40.4 parts of Radix Ophiopogonis, 11.5 parts of the Radix Aucklandiae, 11.5 parts of Radix Et Rhizoma Rhei; 40.4 parts of Fructus Chebulaes, 8.6 parts of artificial Calculus Boviss, 1.15 parts of artificial Moschuss.
Select materials: choose above-mentioned various raw material by standard, wherein, mainly detect content and be: the ginseng ketone first II of Radix Salviae Miltiorrhizae
A, Tanshinone I I
B, cryptotanshinone, saivianic acid A, danshensuan B, protocatechuic acid etc.Volatile oil such as the alantolactone of Radix Inulae, inulin, content is 1%-2%.Fructus Choerospondiatis is mainly grasped the Fructus Choerospondiatis total flavones.Semen Myristicae major control composition is volatile oil such as pinene, sabinene, lauro lene, myristicin, content 5%-15%.The Lignum Dalbergiae Odoriferae main component is-volatile oil such as β heerabolene, β-farnesene.Lignum Santali Albi contains volatile oil 1.6%-6%, and main component is α or β santalol, reaches more than 90%, and contains sesquiterpenoidss such as α or β santalene.Fructus Gardeniae contains multiple iridoid glycoside constituents, and jasminoidin, Gardenoside etc. are arranged.The Radix Astragali contains Saponin class polysaccharide, flavonoid etc.The Flos Carthami main component is a saffloside.Radix Notoginseng contains total Saponin about 12%.The main component of Calculus Bovis is bilirubin, cholic acid etc.The Moschus main component is a muscone.Other drug is mainly controlled by its appearance characteristics.
Process choice: mainly, select for use suitable solvent to extract, the thin medical material expensive and that mealiness is strong of fragrance is adopted directly to pulverize participate in granulating according to the effective ingredient and the physicochemical property thereof of various raw materials.To the contained tanshinone component of Radix Salviae Miltiorrhizae, Radix Inulae volatile oil composition adopts alcohol reflux, also can adopt supercritical extraction technique.Fructus Choerospondiatis, the Radix Astragali, Fructus Gardeniae, Flos Carthami etc. are mainly water soluble ingredient together with the medicinal residues after Radix Salviae Miltiorrhizae, the Radix Inulae alcohol extraction, with water boiling and extraction, also can adopt the continuous flow upstream ultrasonic technology to extract.For effective ingredient is fully extracted, determined best granularity, solvent quantity and extraction time by the quadrature method for testing, guaranteed optimum extraction efficient.For guaranteeing product quality, adopt thin layer chromatography scanning that its intermediate is carried out quality control simultaneously.Alcohol extract is surveyed wherein contained tanshinone during with relative density 1.38 (55 ℃-60 ℃), must not be less than 0.9%, and water extract surveys that wherein contained jasminoidin is not all right to be less than 0.2% during with relative density 1.21 (80 ℃-85 ℃).Effective ingredient complexity such as Semen Myristicae, Lignum Santali Albi, Lignum Aquilariae Resinatum, Radix Notoginseng, and contain fragrant ingredient more, mealiness is stronger.For preventing that effective ingredient scatters and disappears, it is pulverized coarse powder, be ground into the fine powder mixing for standby use with thin precious medicinal material again.All mixing fine powders add appropriate amount of auxiliary materials.Granulate with suitable wetting agent, natural drying, incapsulates granulate.
Processing instance: after choosing the prescription crude drug by standard, with Radix Salviae Miltiorrhizae, Radix Inulae decoction pieces, add 3 times of amount alcohol reflux 1.5 hours, filter, medicinal residues are standby, and are standby behind the decompression filtrate recycling ethanol; Fructus Choerospondiatis, the Radix Astragali, Fructus Gardeniae, Flos Carthami, Fructus Toosendan, Radix Rubiae, Radix Ophiopogonis, Radix Et Rhizoma Rhei, Fructus Chebulae's 9 flavors are merged with above-mentioned medicinal residues, and decocting boils 2 times, each 2 hours, gradation filters, and merging filtrate adds Radix Salviae Miltiorrhizae, Radix Inulae extracting solution, be condensed into relative density and be the thick paste of 1.21 (80-85 ℃), standby; Lignum Dalbergiae Odoriferae, Radix Notoginseng, Semen Myristicae, Lignum Santali Albi, Radix Et Rhizoma Rhei 5 flavor medicine mixed powders are broken into powder, mix thoroughly with above-mentioned thick paste, dry below 60 ℃; be ground into fine powder, convert with artificial Moschus, artificial Calculus Bovis's fine powder and be mixed evenly, granulate; natural drying becomes brown granular, 1000 capsules of packing into, 90.3g/ grain.
Claims (3)
- A mongolian medicine Poly for the treatment of hyperlipemia you; it is characterized in that: this mongolian medicine is to be made by following bulk drugs: Fructus Choerospondiatis 110-120 part; Radix Salviae Miltiorrhizae 110-120 part, Radix Inulae 110-120 part, Semen Myristicae 18-30 part; Fructus Gardeniae 35-45 part; Lignum Santali Albi 18-30 part, Radix Astragali 52-65 part, Lignum Dalbergiae Odoriferae 35-45 part; Flos Carthami 35-45 part; Radix Notoginseng 35-45 part, Fructus Toosendan 35-45 part, Radix Rubiae 52-65 part; Radix Ophiopogonis 35-45 part; Radix Aucklandiae 8-15 part, Radix Et Rhizoma Rhei 8-15 part, Fructus Chebulae 35-45 part; Calculus Bovis 5-12 part, Moschus 0.5-1.8 part.
- 2. a kind of mongolian medicine Poly that for the treatment of hyperlipemia according to claim 1; it is characterized in that: the weight portion of above-mentioned raw materials medicine is: Fructus Choerospondiatis 114-118 part; Radix Salviae Miltiorrhizae 114-118 part, Radix Inulae 114-118 part, Semen Myristicae 20-25 part; Fructus Gardeniae 38-42 part; Lignum Santali Albi 20-25 part, Radix Astragali 56-60 part, Lignum Dalbergiae Odoriferae 38-42 part; Flos Carthami 38-42 part; Radix Notoginseng 38-42 part, Fructus Toosendan 38-42 part, Radix Rubiae 56-60 part; Radix Ophiopogonis 38-42 part; Radix Aucklandiae 10-12 part, Radix Et Rhizoma Rhei 10-12 part, Fructus Chebulae 38-42 part; Calculus Bovis 7-10 part, Moschus 0.8-1.3 part.
- 3. a kind of mongolian medicine Poly that for the treatment of hyperlipemia according to claim 1, it is characterized in that: the weight portion of above-mentioned raw materials medicine is: 116 parts of Fructus Choerospondiatis, 116 parts of Radix Salviae Miltiorrhizaes, 116 parts of Radix Inulaes; 23 parts of Semen Myristicaes, 40.4 parts of Fructus Gardeniaes, 23 parts in Lignum Santali Albi; 58 parts of the Radixs Astragali, 40.4 parts of Lignum Dalbergiae Odoriferaes, 40.4 parts on Flos Carthami; 40.4 parts of Radix Notoginseng, 40.4 parts of Fructus Toosendans, 58 parts in Radix Rubiae; 40.4 parts of Radix Ophiopogonis, 11.5 parts of the Radix Aucklandiae, 11.5 parts of Radix Et Rhizoma Rhei; 40.4 parts of Fructus Chebulaes, 8.6 parts of artificial Calculus Boviss, 1.15 parts of artificial Moschuss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100804253A CN100409880C (en) | 2006-05-15 | 2006-05-15 | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100804253A CN100409880C (en) | 2006-05-15 | 2006-05-15 | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1879839A CN1879839A (en) | 2006-12-20 |
| CN100409880C true CN100409880C (en) | 2008-08-13 |
Family
ID=37518340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100804253A Active CN100409880C (en) | 2006-05-15 | 2006-05-15 | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100409880C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102698185B (en) * | 2012-07-09 | 2013-06-19 | 宋永心 | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof |
| CN104258135A (en) * | 2014-09-23 | 2015-01-07 | 苏州市天灵中药饮片有限公司 | Soft health capsule for lowering blood pressure and reducing blood fat and preparation method of soft health capsule |
| CN106109645A (en) * | 2016-07-03 | 2016-11-16 | 张俊清 | A kind of mongolian medicine compositions treating cattle thermoplegia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356138A (en) * | 2001-09-27 | 2002-07-03 | 孔金立 | Medicine for treating cardiovascular and cerebrovascular diseases of old people |
-
2006
- 2006-05-15 CN CNB2006100804253A patent/CN100409880C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356138A (en) * | 2001-09-27 | 2002-07-03 | 孔金立 | Medicine for treating cardiovascular and cerebrovascular diseases of old people |
Non-Patent Citations (2)
| Title |
|---|
| 蒙药治疗高脂血症的临床研究. 白音孟和，包光华，孟和宝鲁，塔木.中国民族医药杂志，第9卷第1期. 2003 |
| 蒙药治疗高脂血症的临床研究. 白音孟和，包光华，孟和宝鲁，塔木.中国民族医药杂志，第9卷第1期. 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1879839A (en) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102671137B (en) | Medicine composition for treating diabetic nephropathy and preparation method of medicine composition | |
| CN102233119A (en) | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof | |
| CN103041209B (en) | Chinese herbal preparation for curing deficiency of kidney-yin and preparation method thereof | |
| CN105943615A (en) | Application of whole hemp extract in preparation of pancreatic cancer treating drug | |
| CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
| CN103749818B (en) | A kind of sealwort hypoglycemic health protection tea and preparation method thereof | |
| CN105935374A (en) | Application of Quanmasu in preparation of drugs for treatment of diabetes | |
| CN100409880C (en) | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN102266052A (en) | Health care food with function of improving sleeping | |
| CN102580024B (en) | Composition for treating cardiovascular diseases | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN101085121A (en) | Traditional Chinese medicine composition with hypoglycemic and antilipemic function and making method and application | |
| CN111110735A (en) | Lipid-lowering pharmaceutical composition, preparation method and application | |
| CN105998194A (en) | Antithrombotic medicine | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
| AU2004318154B2 (en) | Pharmaceutics of traditional chinese medicine of treating aids and preparation method thereof | |
| CN104645015A (en) | Traditional Chinese medicine compound preparation for treating vascular dementia and preparation method of traditional Chinese medicine compound preparation | |
| CN105533749B (en) | It is a kind of containing Herba Epimedii, the health food of Schisandra chinensis and its preparation method and application | |
| CN103721187A (en) | Blood-circulation-promoting and blood-fat-reducing pill for treating hyperlipemia and preparation method of pill | |
| CN100488546C (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN101797365B (en) | Preparation technology of Kaixiong Shunqi Jiaonang | |
| CN105362629A (en) | Female climacteric syndrome treatment pharmaceutical composition containing cortex eucommiae and preparation method of female climacteric syndrome treatment pharmaceutical composition containing cortex eucommiae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mongolian medicine Baolier for treating hyperlipemia and method for preparing same Effective date of registration: 20130829 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2013990000619 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 028011 west section of Liao River Street, Tongliao economic and Technological Development Zone, the Inner Mongolia Autonomous Region Patentee after: Inner Mongolia Medicine Co., Ltd. Address before: 028007, the Inner Mongolia Autonomous Region, Tongliao, Horqin Road, Tong Cheng Road No. 18 Patentee before: Inner Mongolia Medicine Co., Ltd. |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20141011 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2013990000619 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mongolian medicine Baolier for treating hyperlipemia and method for preparing same Effective date of registration: 20141013 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2014990000845 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160113 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2014990000845 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mongolian medicine Baolier for treating hyperlipemia and method for preparing same Effective date of registration: 20160113 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2016990000034 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170713 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2016990000034 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mongolian medicine Baolier for treating hyperlipemia and method for preparing same Effective date of registration: 20170713 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2017990000634 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20181130 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2017990000634 |